Pricing trend for cancer drugs just isn’t sustainable
Regarding the article “Will the cost of cancer drugs break the economy?” (ModernHealthcare.com, March 14), this is not a new question, since in the early 2000s the New England Journal of Medicine published an article showing the very minimal improvement in longevity vs. the excessive pricing of new cancer drugs.
Currently, patients and their insurance companies lose because there’s no free market to check and balance pricing vs. value. It’s all about “Big Pharma” pushing profiteering without boundaries. As well, to what extent are a select group of community oncologists oblivious to this point, given the higher profit they derive from the costlier drugs?
Given the cohort of aging baby boomers, watch how the excessive pricing of cancer drugs eventually leads to a form of single-payer, given how nobody will be able to afford their Medicare Part D and everybody demands the latest miracle drug without consciously thinking about the cost and its efficacy. Ironically, although Big Pharma’s marketing prowess has encouraged such patient demands, it will eventually be pharma’s downfall, as more patients won’t be able to afford these drugs. M.E. Singer